Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM

Radhika Srinivasan, Joanna J. Phillips, Scott R.Vanden Berg, Mei-Yin Polley, Gabriela Bourne, Alvin Au, Andrea Pirzkall, Soonmee Cha, Susan M. Chang, Sarah J. Nelson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The motivation of this study was to address the urgent clinical problem related to the inability of magnetic resonance (MR) imaging measures to differentiate tumor progression from treatment effects in patients with glioblastoma multiforme (GBM). While contrast enhancement on MR imaging (MRI) is routinely used for assessment of tumor burden, therapy response, and progression- free survival in GBM, it is well known that changes in enhancement following treatment are nonspecific to tumor. To address this issue, the objective of this study was to investigate whether MR spectroscopy can provide improved biomarker surrogates for tumor following treatment. High-resolution metabolic profiles of tissue samples obtained from patients with GBM were directly correlated with their pathological assessment to determine metabolic markers that correspond to pathological indications of tumor or treatment effects. Acquisition of tissue samples with image guidance enabled the association of ex vivo biochemical and pathological properties of the tissue samples with in vivo MR anatomical and structural properties derived from presurgical MR images. Using this approach, we found that metabolic concentration levels of [Myo-inositol/total choline (MCI)] in tissue samples are able to differentiate tumor from nontumor and treatment-induced reactive astrocytosis with high significance (P < .001) in newly diagnosed and recurrent GBM. The MCI index has a sensitivity of 93% to tumor in recurrent GBM and delineates the contribution of cellularity that originates from tumor and astrocytic proliferation following treatment. Low levels of MCI for tumor were associated with a reduced apparent diffusion coefficient and elevated choline-N-acetyl-aspartate index derived from in vivo MR images.

Original languageEnglish (US)
Pages (from-to)1152-1161
Number of pages10
JournalNeuro-Oncology
Volume12
Issue number11
DOIs
StatePublished - Nov 1 2010
Externally publishedYes

Fingerprint

Glioblastoma
Magnetic Resonance Spectroscopy
Choline
Inositol
Neoplasms
Therapeutics
Magnetic Resonance Imaging
Gliosis
Metabolome
Tumor Biomarkers
Tumor Burden
Disease-Free Survival

Keywords

  • GBM
  • MR spectroscopy
  • Myo-inositol
  • Treatment effect

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Srinivasan, R., Phillips, J. J., Berg, S. R. V., Polley, M-Y., Bourne, G., Au, A., ... Nelson, S. J. (2010). Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro-Oncology, 12(11), 1152-1161. https://doi.org/10.1093/neuonc/noq075

Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. / Srinivasan, Radhika; Phillips, Joanna J.; Berg, Scott R.Vanden; Polley, Mei-Yin; Bourne, Gabriela; Au, Alvin; Pirzkall, Andrea; Cha, Soonmee; Chang, Susan M.; Nelson, Sarah J.

In: Neuro-Oncology, Vol. 12, No. 11, 01.11.2010, p. 1152-1161.

Research output: Contribution to journalArticle

Srinivasan, R, Phillips, JJ, Berg, SRV, Polley, M-Y, Bourne, G, Au, A, Pirzkall, A, Cha, S, Chang, SM & Nelson, SJ 2010, 'Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM', Neuro-Oncology, vol. 12, no. 11, pp. 1152-1161. https://doi.org/10.1093/neuonc/noq075
Srinivasan, Radhika ; Phillips, Joanna J. ; Berg, Scott R.Vanden ; Polley, Mei-Yin ; Bourne, Gabriela ; Au, Alvin ; Pirzkall, Andrea ; Cha, Soonmee ; Chang, Susan M. ; Nelson, Sarah J. / Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. In: Neuro-Oncology. 2010 ; Vol. 12, No. 11. pp. 1152-1161.
@article{9bcfda2743c64fca95d3a32dd5d9b6be,
title = "Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM",
abstract = "The motivation of this study was to address the urgent clinical problem related to the inability of magnetic resonance (MR) imaging measures to differentiate tumor progression from treatment effects in patients with glioblastoma multiforme (GBM). While contrast enhancement on MR imaging (MRI) is routinely used for assessment of tumor burden, therapy response, and progression- free survival in GBM, it is well known that changes in enhancement following treatment are nonspecific to tumor. To address this issue, the objective of this study was to investigate whether MR spectroscopy can provide improved biomarker surrogates for tumor following treatment. High-resolution metabolic profiles of tissue samples obtained from patients with GBM were directly correlated with their pathological assessment to determine metabolic markers that correspond to pathological indications of tumor or treatment effects. Acquisition of tissue samples with image guidance enabled the association of ex vivo biochemical and pathological properties of the tissue samples with in vivo MR anatomical and structural properties derived from presurgical MR images. Using this approach, we found that metabolic concentration levels of [Myo-inositol/total choline (MCI)] in tissue samples are able to differentiate tumor from nontumor and treatment-induced reactive astrocytosis with high significance (P < .001) in newly diagnosed and recurrent GBM. The MCI index has a sensitivity of 93{\%} to tumor in recurrent GBM and delineates the contribution of cellularity that originates from tumor and astrocytic proliferation following treatment. Low levels of MCI for tumor were associated with a reduced apparent diffusion coefficient and elevated choline-N-acetyl-aspartate index derived from in vivo MR images.",
keywords = "GBM, MR spectroscopy, Myo-inositol, Treatment effect",
author = "Radhika Srinivasan and Phillips, {Joanna J.} and Berg, {Scott R.Vanden} and Mei-Yin Polley and Gabriela Bourne and Alvin Au and Andrea Pirzkall and Soonmee Cha and Chang, {Susan M.} and Nelson, {Sarah J.}",
year = "2010",
month = "11",
day = "1",
doi = "10.1093/neuonc/noq075",
language = "English (US)",
volume = "12",
pages = "1152--1161",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM

AU - Srinivasan, Radhika

AU - Phillips, Joanna J.

AU - Berg, Scott R.Vanden

AU - Polley, Mei-Yin

AU - Bourne, Gabriela

AU - Au, Alvin

AU - Pirzkall, Andrea

AU - Cha, Soonmee

AU - Chang, Susan M.

AU - Nelson, Sarah J.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - The motivation of this study was to address the urgent clinical problem related to the inability of magnetic resonance (MR) imaging measures to differentiate tumor progression from treatment effects in patients with glioblastoma multiforme (GBM). While contrast enhancement on MR imaging (MRI) is routinely used for assessment of tumor burden, therapy response, and progression- free survival in GBM, it is well known that changes in enhancement following treatment are nonspecific to tumor. To address this issue, the objective of this study was to investigate whether MR spectroscopy can provide improved biomarker surrogates for tumor following treatment. High-resolution metabolic profiles of tissue samples obtained from patients with GBM were directly correlated with their pathological assessment to determine metabolic markers that correspond to pathological indications of tumor or treatment effects. Acquisition of tissue samples with image guidance enabled the association of ex vivo biochemical and pathological properties of the tissue samples with in vivo MR anatomical and structural properties derived from presurgical MR images. Using this approach, we found that metabolic concentration levels of [Myo-inositol/total choline (MCI)] in tissue samples are able to differentiate tumor from nontumor and treatment-induced reactive astrocytosis with high significance (P < .001) in newly diagnosed and recurrent GBM. The MCI index has a sensitivity of 93% to tumor in recurrent GBM and delineates the contribution of cellularity that originates from tumor and astrocytic proliferation following treatment. Low levels of MCI for tumor were associated with a reduced apparent diffusion coefficient and elevated choline-N-acetyl-aspartate index derived from in vivo MR images.

AB - The motivation of this study was to address the urgent clinical problem related to the inability of magnetic resonance (MR) imaging measures to differentiate tumor progression from treatment effects in patients with glioblastoma multiforme (GBM). While contrast enhancement on MR imaging (MRI) is routinely used for assessment of tumor burden, therapy response, and progression- free survival in GBM, it is well known that changes in enhancement following treatment are nonspecific to tumor. To address this issue, the objective of this study was to investigate whether MR spectroscopy can provide improved biomarker surrogates for tumor following treatment. High-resolution metabolic profiles of tissue samples obtained from patients with GBM were directly correlated with their pathological assessment to determine metabolic markers that correspond to pathological indications of tumor or treatment effects. Acquisition of tissue samples with image guidance enabled the association of ex vivo biochemical and pathological properties of the tissue samples with in vivo MR anatomical and structural properties derived from presurgical MR images. Using this approach, we found that metabolic concentration levels of [Myo-inositol/total choline (MCI)] in tissue samples are able to differentiate tumor from nontumor and treatment-induced reactive astrocytosis with high significance (P < .001) in newly diagnosed and recurrent GBM. The MCI index has a sensitivity of 93% to tumor in recurrent GBM and delineates the contribution of cellularity that originates from tumor and astrocytic proliferation following treatment. Low levels of MCI for tumor were associated with a reduced apparent diffusion coefficient and elevated choline-N-acetyl-aspartate index derived from in vivo MR images.

KW - GBM

KW - MR spectroscopy

KW - Myo-inositol

KW - Treatment effect

UR - http://www.scopus.com/inward/record.url?scp=78650102881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650102881&partnerID=8YFLogxK

U2 - 10.1093/neuonc/noq075

DO - 10.1093/neuonc/noq075

M3 - Article

C2 - 20647244

AN - SCOPUS:78650102881

VL - 12

SP - 1152

EP - 1161

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

IS - 11

ER -